Market & Industry Briefs
Executive Summary
Brief summaries of recent medtech market and industry developments. This month we cover FDA panels' thumbs-down rulings on Styker's OP1-Putty and Therox's SuperSaturated Oxygen Therapy System, a potential curb on payments for negative pressure wound therapy pumps, CMS' review of carotid stenting coverage, and Abbott Vascular move into the second phase of its ABSORB trial for its drug-eluting stent.
You may also be interested in...
Bioactive Technologies For Bone Replacement
Expanded indications for bone morphogenetic proteins and new alternatives to those first-generation bone growth factors have the potential to grow the $2 billion market for bone replacement materials. This article is reprinted from the April 2010 issue of Medtech Insight (Also see "Bioactive Technologies for Bone Replacement" - Medtech Insight, 1 Apr, 2010.).
Bioactive Technologies for Bone Replacement
The global market for orthobiologics, comprised primarily of bone replacement materials, reached almost $2 billion in 2009 and is growing at an overall rate of 7%. Medtronic leads in bone replacement with a 45% market share, but overall growth in orthobiologics may come from emerging segments, particular synthetic and stem-cell based technologies.
Bioactive Technologies for Bone Replacement
The global market for orthobiologics, comprised primarily of bone replacement materials, reached almost $2 billion in 2009 and is growing at an overall rate of 7%. Medtronic leads in bone replacement with a 45% market share, but overall growth in orthobiologics may come from emerging segments, particular synthetic and stem-cell based technologies.